EGFR/CDK2-IN-1

EGFR/CDK2-IN-1 (Compound 3b) is an EGFR/CDK2 inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research[1].

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

Signaling Pathways >> Cell Cycle/DNA Damage >> CDK

EGFR, CDK-2[1].

EGFR/CDK2-IN-1 (0-20 μM; 48 h) shows excellent activity in both MCF7 and HepG2 with IC50 values of 4.1 and 3.5 μM, respectively[1]. Cell Cytotoxicity Assay[1] Cell Line: MCF7, HepG2 cells Concentration: 0-20 μM Incubation Time: 48 h Result: Exhibited good cytotoxic activity in breast and liver cancer cells.